Management of precursor lesions of cervical carcinoma: History, host defense, and a survey of modalities

Obstetrics and Gynecology Clinics of North America

Volumn 29, Issue 4, 2002, Pages 751-785

  Cox, J Thomas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; BETA CAROTENE; CANCER VACCINE; CIDOFOVIR; FLUOROURACIL; FOLIC ACID; IMIQUIMOD; INTERFERON; ORAL CONTRACEPTIVE AGENT; TRICHLOROACETIC ACID; VACCINE;

CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CARBON DIOXIDE LASER; COLPOSCOPY; CRYOSURGERY; CYTODIAGNOSIS; DIATHERMY; DIET; DISEASE COURSE; ELECTROSURGERY; FEMALE; HOST RESISTANCE; HUMAN; HYSTERECTOMY; IMMUNE RESPONSE; IMMUNOTHERAPY; PHOTODYNAMIC THERAPY; PRECANCER; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; UTERINE CERVIX CYTOLOGY; VIRAL GENE THERAPY; VIRUS LOAD; WART VIRUS;

ANTIVIRAL AGENTS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 0036920182     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(02)00048-7     Document Type: Review

References (156)

1. Williams J. Cancer of the uterus. Harveian Lectures for 1886. London: HK Lewis; 1886.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 18 major cancers in 1985. Int J Cancer 1993;54:594-606.
3. Cox JT. Management of cervical intraepithelial neoplasia. Lancet 1999;353:857-9.
4. Mitchell MF, Tortolero-Luna G, Cook E, et al. A randomized clinical trial of cryotherapy, loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gyneol 1998;92:737-44.
5. Soutter WP, De Barros Lopez A, Fletcher A, et al. Invasive cervical cancer after conservative treatment for cervical intraepithelial neoplasia. Lancet 1997;349:978-80.
6. Cox JT. Answer to: "How long will screening myths survive?" Lancet 2000
7. Patsner B. Diagnosis and contemporary management of cervical intraepithelial neoplasia. In: Rock JA, Faro S, Gant NF, et al, editors. Advances in Obstetrics and Gynecology. 1994. p. 261-82.
8. Devesa SS. Descriptive epidemiology of cancer of the uterine cervix. Obstet Gynecol 1984;63:605-12.
9. Krone KR, Kiviat NB, Koutsky LA. The epidemiology of cervical neoplasms. In: Luesley D, Jordan J, Richart RM, editors. Intraepithelial Neoplasia of the Lower Genital Tract. Edinburgh: Churchill Livingston; 1995. p. 49-60.
10. Koss LG, Durfee GR. Unusual patterns of squamous epithelium of the uterine cervix: Cytologic and pathologic study of koilocytotic atypia. Ann N Y Acad Sci 1956;63:1245-61.
11. Meisels A, Fortein R. Condylomatous lesions of the cervix and vagina. I. Cytologic patterns. Acta Cytol 1976;20:505-9.
12. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
13. Wright TC, Cox JT, Massad LS, et al for the 2001 ASCCP-Sponsored Consensus Workshop. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities and cervical cancer precursors - Part I. Cytological abnormalities. JAMA 2002;287 (18):2120-9.
14. Babes A. Diagnostic du cancer du col uterine par les frottis. La Presse Medicale 1928;36:451. Acta Cytol 1967;11:217 [reprinted in English].
15. Babes A. Diagnostic du cancer du col uterine par les frottis. La Presse Medicale 1928;36:451. Acta Cytol 1967;11:217 [reprinted in English].
16. Papanicolaou GN. Lecture (Data on Vaginal Smears) 1928.
17. Papanicolaou GN, Traut HF. Diagnosis of Uterine Cancer by the Vaginal Smear. New York: Commonwealth Fund; 1943
18. Hinselmann H. Der begriff der umwandlungszone der portio. Arch Gynakol 1927;131:422-4.
19. Hinselmann H. Die kolposkopie. In: Klinische Fortbildung. Neue Deutsche Klinik 1936;717(Suppl 4);10.
20. Torres JE, Riopelle MA. History of colposcopy in the United States. Obstet Gynecol Clin N Amer 1993;20:1-12.
21. Younge PA, Hertig A, Armstrong D. A study of carcinoma in situ of the cervix - 135 Cases. Am J Obstet Gynecol 1949;58:867-95.
22. Burke L. Evolution of therapeutic approaches to cervical intraepithelial neoplasia. J Lower Genital Tract Dis 1997;1:267-73.
23. Richart RM, Sciarra JJ. Treatment of cervical dysplasia by outpatient electrocauterization. Am J Obstet Gynecol 1968;101:200-3.
24. Chanen W, Rome RM. Electrocoagulation diathermy for cervical dysplasia and carcinoma-insitu: A 15-year survey. Obstet Gynecol 1983;67:673-5.
25. Galvin GA, Telinde RW. The present-day status of non-invasive cervical carcinoma. Am J Obstet Gynecol 1949;57:15-20.
26. Graham JB, Meigs JV. Recurrence of tumor after total hysterectomy for carcinoma in situ. Am J Obstet Gynecol 1952;64:1159-62.
27. Kreiger JS, McCormack LJ. Graded treatment for in situ carcinoma of the uterine cervix. Am J Obstet Gynecol 1968;101:172-82.
28. Lisfranc MT. Memoire sur l'amputation du col de l'uterus. Gaz Med Par 2.S 1834;2:385-9 [in French].
29. Cox JT. Triage of the abnormal Pap smear. Lab Clin N Am 2000
30. Jones DED, Creaseman WT, Dombroski RA, et al. Evaluation of the atypical Pap smear. Am J Obstet Gynecol 1987;157:544-9.
31. Mayeaux EJ, Harper MB, Abreo F, et al. A comparison of the reliability of repeat cervical smears and colposcopy in patients with abnormal cervical cytology. J Fam Prac 1995;40:57-62.
32. Richart RM. A clinical staining test for the in vivo delineation of dysplasia and carcinoma in situ. Am J Obstet Gynecol 1963;86:703-4.
33. Richart RM, Sciarra JJ. Treatment of cervical dysplasia by outpatient electrocauterization. Am J Obstet Gynecol 1968;101:200-3.
34. Creaseman WT, Weed JC, Curry SL, et al. Efficacy of cryosurgical treatment of severe cervical intraepithelial neoplasia. Obstet Gynecol 1972;41:501-5.
35. Wright VC, Davies E, Riopelle MA. Laser surgery for cervical intraepithelial neoplasia: Principles and results. Am J Obstet Gynecol 1983;145:181-4.
36. Prendiville W, Cullimore J, Norman S. Large loop excision of the transformation zone (LLETZ): A new method of management for women with intraepithelial neoplasia. Br J Obstet Gynecol 1989;96:1054-60.
37. Tate DR, Anderson RJ. Recurrence of cervical dysplasia in the human immunodeficiency virus-seropositive paitent. Obstet Gynecol 2001;97(Suppl 1):S60.
38. Crowley-Nowick PA, Bell M, Edwards RP, et al. Normal uterine cervix: Characterization of isolated lymphocyte phenotypes and immunoglobulin secretion. Am J Reprod Immunol 1995;34(4):241-7.
39. Tyring SK, Arany II, Stanley MA, et al. Mechanism of action of imiquimod 5% cream in the treatment of anogenital warts. Prim Care Update Ob Gyns 1998;5(4):151-2.
40. Chow LT, Broker TR. Papillomavirus DNA replication. Intervirology 1994;37:150-8.
41. Cheng S, Schmidt-Grimminger D-C, Murant T, et al. Differentiation-dependent up-regulation of the human papillomavirus gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev 1995;9:2335-49.
42. Dollard SC, Wilson JL, Demeter LM, et al. Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. Genes Dev 1992;6:1131-42.
43. Flores ER, Lambert PF. Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle. J Virol 1997;71:7167-79.
44. Jian Y, Schmidt-Grimminger D-C, Chien W-M, et al. Post-transcriptional induction of p21cip 1 protein by human papillomavirus E7 inhibits unscheduled DNA synthesis reactivated in differentiated keratinocytes. Oncogene 1998;17:2027-38.
45. Dyson N, Howley PM, Munger K, et al. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-6.
46. Wemess BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-9.
47. Nuovo GJ, Banbury R, Calayag PT. Human papillomavirus types and recurrent cervical warts in immunocompromised women. Mod Pathol 1991;4:632-5.
48. Ylitalo N, Sorensen P, Josefsson AM, et al. Consistent high viral load of human papilloma-virus 16 and risk of cervical carcinoma in situ: A nested case-control study. Lancet 2000;355:2194-8.
49. Connor JP, Ferrer K, Kane JP, et al. Evaluation of Langerhans' cells in the cervical epithelium of women with cervical intraepithelial neoplasia. Gynecol Oncol 1999;75:130-5.
50. Hildesheim A, Schiffman MH, Tsukui T, et al. Immune activation in cervical neoplasia: Cross-sectional association between plasma soluble interleukin 2 receptor levels and disease. Cancer Epidemiol Biomarkers Prev 1997;6:807-13.
51. Tsukui T, Hildesheim A, Schiffman MH, et al. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: Correlation with cervical pathology. Cancer Res 1996;56:3697-74.
52. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
53. Nobbenhuis M, Walboomers JM, Helmerhorst T, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study. Lancet 1999;354:20.
54. Hopman EH, Rozendaal L, Voorhorst FJ, et al. High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. BJOG 2000;107(5):600-4.
55. Pride G, Chuprevich TW. Topical 5-fluorouracil treatment of the transformation zone intraepithelial neoplasia of cervix and vagina. Obstet Gynecol 1982;60:467-72.
56. Barten G. Local treatment of cervical intraepithelial neoplasia with a 5 percent fluorouracil ointment. Zentralbl Gynakol 1987;109:1510-6.
57. Goodman A, Zukerberg LR, Nikrui N, et al. Vaginal adenosis and clear cell carcinomas after 2-fluorouracil treatment for condylomas. Cancer 1991;68:1628-32.
58. Sidhu HK, Price JH, McCarron PA, et al. A randomised controlled trial evaluating a novel cytotoxic drug delivery system for the treatment of cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1999;104:145-9.
59. Woolfson AD, McCafferty DF, McCarron PA, et al. Autoradiographic imaging of the distribution of 5-fluorouracil through cervical tissue following in vitro surface application of a bioadhesive cervical patch. Pharm Res 1995;12:676-81.
60. Maiman M, Watts DH, Andersen J, et al. Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: A randomized trial. Obstet Gynecol 1999;94:954-61.
61. Chanen W, Rome RM. Electrocoagulation diathermy for cervical dysplasia and carcinoma-insitu: A 15-year survey. Obstet Gynecol 1983;67:673.
62. Seshadri L, Cope J. The diagnosis, treatment and complications of CIN. Aust N Z J Obstet Gynaecol 1985;25:208.
63. Giles JA, Walker PC, Chalk PA. The treatment of CIN by radical electrocoagulation diathermy: Five years' experience. Br J Obstet Gynaecol 1987;94:1089.
64. Singer A, Monaghan JM, Quek SC. Lower Genital Tract Precancer: Colposcopy, Pathology and Treatment. 2nd Edition. Oxford, UK: Blackwell Science Ltd; 2000.
65. Kwikkel HJ, Helmerhorst TJM, Bezemer PD, et al. Laser or cryotherapy for cervical intraepithelial neoplasia: A randomized study to compare efficacy and side effects. Gynecol Oncol 1985;22:23-31.
66. Ostergard DR. Cryosurgical treatment of cervical intraepithelial neoplasia. Obstet Gynecol 1980;56:231-3.
67. Morrow CP, Townsend DE. Synopsis of Gynecologic Oncology. 3rd Edition. New York: John Wiley and Sons; 1987.
68. Stuart GCE, Anderson RJ, Corlett BMA, et al. Assessment of failures of cryosurgical treatment in cervical intraepithelial neoplasia. Am J Obstet Gynecol 1982;142:658-63.
69. Hatch KD, Shingleton HM, Austin JM, et al. Cryosurgery of cervical intraepithelial neoplasia. Obstet Gynecol 1981;57:692.
70. Savage EW, Matlock DL, Salem FA, et al. The effect of endocervical gland involvement on the cure rates of patients with cervical intraepithelial neoplasia undergoing cryosurgery. Gynecol Oncol 1982;14:194.
71. Townsend DE, Richart RM. Cryotherapy and carbon dioxide laser management of cervical intraepithelial neoplasia: A controlled comparison. Obstet Gynecol 1983;61:75.
72. Creasman WT, Hinshaw WM, Clarke-Pearson DL. Cryosurgery in the management of cervical intraepithelial neoplasia. Obstet Gynecol 1984;63:145.
73. Ferenczy A. Comparison of cryo and carbon dioxide laser therapy for cervical intraepithelial neoplasia. Obstet Gynecol 1985;66:793.
74. Wright CV, Riopelle MA. The geometry of cervical intraepithelial neoplasia as a guide to its eradication. Cervix Lower Female Genital Tract 1986;4:21-38.
75. Tsukamoto N. Treatment of cervical intraepithelial neoplasia with carbon dioxide laser. Gynecol Oncol 1985;21:331-6.
76. 2 laser versus cryotherapy, a randomized clinical trial. Acta Obstet Gynecol Scand 1987;66:531-6.
77. Benedet JL, Miller DM, Nickerson KC. Results of conservative management of cervical intraepithelial neoplasia. Obstet Gynecol 1992;79:105.
78. Paraskevaidis E, Jandial L, Mann EM, et al. Patterns of treatment failure following laser for cervical intraepithelial neoplasia; implication for follow-up protocol. Obstet Gynecol 1991;78:80.
79. Pearson SE, Whittaker J, Ireland D, et al. Invasive cancer of the cervix after laser treatment. Br J Obstet Gynaecol 1989;96:486.
80. 2 laser in treatment of carcinoma in situ (CIN III) of the uterine cervix. Gynecol Oncol 1985;22:195.
81. Younge PA. Pre-malignant lesions of the cervix: Clinical management. Clin Obstet Gynecol 1962;5:1137-47.
82. Tronstadt SE, Kirschner K. Treatment of cervical in- traepithelial neoplasia with local excision biopsy and cryosurgery. Acta Obstet Gynecol Scand 1980;59:349-53.
83. Cartier I, Richart RM, Wright TC. The evolution of loop diathermy in cervical disease. In: Prendiville W, editor. Large Loop Excision of the Transformation Zone: A Practical Guide to LLETZ. London: Chapman and Hall Medical; 1996. p. 93-7.
84. Cartier R. Therapeutic choices in treatment. In: Cartier R, editor. Practical Colposeopy. Paris: Laboratoire Cartier; 1984. p. 162.
85. Wright TC, Gagnon S, Richart RM, et al. Treatment of cervical intraepithelial neoplasia using the loop electrosurgical excision procedure. Obstet Gynecol 1992;79:173-8.
86. Luesley DM, Cullimore J, Lawton FG, et al. Loop diathermy excision of the cervical transformation zone in patients with abnormal cervical smears. Br J Med 1990;330:1690-3.
87. Gunasekera PC, Phipps JH, Lewis BV. Large-loop excision of the transformation zone (LLETZ) compared to carbon dioxide laser in the treatment CIN: A superior mode of treatment. Br J Obstet Gynaecol 1990;97:995-8.
88. Whitely PF, Olah KS. Treatment of cervical intraepithelial neoplasia: Experience with low-voltage diathermy loop. Am J Obstet Gynecol 1990;162:1272-7.
89. Minucci D, Cinel A, Insacco E. Diathermic loop treatment for CIN and HPV lesions. Eur J Gynaecol Oncol 1991;12:385-93.
90. Bigrigg MA, Codling BW, Pearson P, et al. Colposcopic diagnosis and treatment for cervical dysplasia at a single clinic visit. Lancet 1990;336:229-31.
91. Ferenczy A, Choukroun D, Arseneau J. Loop electrosurgical excision procedure for squamous intraepithelial lesions of the cervix: Advantages and potential pitfalls. Obstet Gynecol 1996;87:332-7.
92. Wiser-Estin M, Niloff J, Burke L. Is loop excision over- utilized in the management of high grade squamous intraepithelial lesions of the cervix? Cervix Lower Female Genital Tract 1995;13:41-5.
93. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: Realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-5.
94. Wright VC, Davies E, Riopelle MA. Laser cylindrical excision to replace conization. Am J Obstet Gynecol 1984;150:704.
95. Baggish MS, Dorsey JH. Carbon dioxide laser for combination excisional-vaporization conization. Am J Obstet Gynecol 1985;151:23.
96. Martzloff KH. Cancer of the cervix uteri: Recognition of early manifestations. JAMA 1938;111:1921-4.
97. Coppleson M, Atkinson KH, Dalrymple JC. Cervical squamous and glandular intraepithelial neoplasia; clinical features and review of management. In: Coppleson M, editor. Gynaecological Oncology. Volume 1, 2nd Edition. Edinburgh: Churchill Livingstone; 1992. p. 594.
98. Peng YM, Peng YS, Childers JM, et al. Concentrations of carotenoids, tocopherols, and retinol in paired plasma and cervical tissue of patients with cervical cancer, precancer, and noncancerous diseases. Cancer Epidemiol Biomarkers Prev 1998;7:347-50.
99. Orr Jr JW, Wilson K, Bodiford C, et al. Corpus and cervix cancer: A nutritional comparison. Am J Obstet Gynecol 1985;153:775-9.
100. Palan PR, Mikhail MS, Goldberg GL, et al. Plasma levels of beta-carotene, lycopene, canthaxanthin, retinol, and alpha- and tau-tocopherol in cervical intraepithelial neoplasia and cancer. Clin Cancer Res 1996;2:181-5.
101. Comerci Jr JT, Runowicz CD, Fields AL, et al. Induction of transforming growth factor beta-1 in cervical intraepithelial neoplasia in vivo after treatment with beta-carotene. Clin Cancer Res 1997;3:157-60.
102. Lehtinen M, Luostarinen T, Youngman LD, et al. Low levels of serum vitamins A and E in blood and subsequent risk for cervical cancer: Interaction with HPV seropositivity. Nutr Cancer 1999;34:229-34.
103. Palan PR, Chang CJ, Mikhail MS, et al. Plasma concentrations of micronutrients during a nine-month clinical trial of beta-carotene in women with precursor cervical cancer lesions. Nutr Cancer 1998;30:46-52.
104. Butterworth Jr CE, Hatch KD, Macaluso M, et al. Folate deficiency and cervical dysplasia. JAMA 1992;267:528-33.
105. Weinstein SJ, Ziegler RG, Frongillo Jr EA, et al. Low serum and red blood cell folate are moderately, but nonsignificantly associated with increased risk of invasive cervical cancer in U.S. women. J Nutr 2001;131:2040-8.
106. Weinstein SJ, Ziegler RG, Selhub J, et al. Elevated serum homocysteine levels and increased risk of invasive cervical cancer in US women. Cancer Causes Control 2001;12:317-24.
107. Potischman N, Brinton LA, Laiming VA, et al. A case-control study of serum folate levels and invasive cervical cancer. Cancer Res 1991;51(18):4785-9.
108. Sedjo RL, Inserra P, Abrahamsen M, et al. Human papillomavirus persistence and nutrients involved in the methylation pathway among a cohort of young women. Cancer Epidemiol Biomarkers Prev 2002;11:353-9.
109. Alberg AJ, Selhub J, Shah KV, et al. The risk of cervical cancer in relation to serum concentrations of folate, vitamin B12, and homocysteine. Cancer Epidemiol Biomarkers Prev 2000;9:761-4.
110. Thomson SW, Heimburger DC, Cornwell PE, et al. Effect of total plasma homocysteine on cervical dysplasia risk. Nutr Cancer 2000;37:128-33.
111. Moore TO, Moore AY, Carrasco D, et al. Human papillomavirus, smoking, and cancer. J Cutan Med Surg 2001;5:323-8.
112. Acladious NN, Sutton C, Mandal D, et al. Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia (CIN). Int J Cancer 2002;98:435-9.
113. Schiffman MH, Haley NJ, Felton JS, et al. Biochemical epidemiology of cervical neoplasia: Measuring cigarette smoke constituents in the cervix. Cancer Res 1987;47(14):3886-8.
114. Hellberg D, Nilsson S, Haley NJ, et al. Smoking and cervical intraepithelial neoplasia: Nicotine and cotinine in serum and cervical mucus in smokers and nonsmokers. Am J Obstet Gynecol 1988;158(4):910-3.
115. Cox JT. The epidemiology of CIN - What is the role of HPV? Ballieres Clinical Obstet Gynecol 1995;9:1-37.
116. Barton SE, Maddox PH, Jenkins D, et al. Effect of cigarette smoking on cervical epithelial immunity: A mechanism for neoplastic change? Lancet 1988;2:652-4.
117. Szarewski A, Maddox P, Royston P, et al. The effect of stopping smoking on cervical Langerhans' cells and lymphocytes. BJOG 2001;10:295-303.
118. Beral V, Hannaford P, Kay C. Oral contraceptive use and malignancies of the genital tract. Results from the Royal College of General Practitioners' Oral Contraception Study. Lancet 1988;2(8624):1331-5.
119. Brinton LA. Oral contraceptives and cervical neoplasia. Contraception 1991;43:581-95.
120. Kjellberg L, Hallmans G, Ahren AM, et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 2000;82:1332-8.
121. Madeleine MM, Daling JR, Schwartz SM, et al. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev 2001;10:171-7.
122. Moreno V, Bosch FX, Munoz N, et al. International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC multicentric case-control study. Lancet 2002;359:1085-92.
123. Butterworth CE, Hatch KD, Gore H, et al. Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives. Am J Clin Nutr 1982;35:73-82.
124. Mittal R, Tsutsumi K, Pater A, et al. Human papillomavirus type 16 expression in cervical keratinocytes: Role of progesterone and glucocorticoid hormones. Obstet Gynecol 1993;81:5-12.
125. Brabin L. Interactions of the female hormonal environment, susceptibility to viral infections, and disease progression. Aids Patient Care Stds 2002;16:211-21.
126. Mitriani-Rosenbaum S, Tsvieli R, Turcapsa R. Estrogen stimulates differential transcription of HPV type 16 in Si HA cervical carcinoma cells. J Gen Virol 1989;70:2227-32.
127. Kim CJ, Um SJ, Kim TY, et al. Regulation of cell growth and HPV genes by exogenous estrogen in cervical cancer cells. Int J Gynecol Cancer 2000;10:157-64.
128. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-84.
129. Connolly DC, Greenspan DL, Wu R, et al. Loss of fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res 2000;6:3505-10.
130. Lin WM, Michalopulos EA, Dhurander N, et al. Allelic loss and microsatellite alterations of chromosome 3p14.2 are more frequent in recurrent cervical dysplasias. Clin Cancer Res 2000;6:1410-4.
131. Bibbo M, Dytch HE, Alenghat E, et al. DNA ploidy profiles as prognostic indicators in CIN lesions. Am J Clin Pathol 1989;92:261-5.
132. Wisman GB, De Jong S, Meersma GJ, et al. Telomerase in (pre)neoplastic cervical disease. Hum Pathol 2000;31:1304-12.
133. Choo CK, Ling MT, Suen CK, et al. Retrovirus-mediated delivery of HPV16 E7 antisense RNA inhibited tumorigenicity of CaSki cells. Gynecol Oncol 2000;78:293-301.
134. He YK, Lui VW, Baar J, et al. Potentiation of E7 anti sense RNA-induced antitumor immunity by co-delivery of IL-12 gene in HPV16 DNA-positive mouse tumor. Gene Ther 1998;5:1462-71.
135. Spitzbart H, Hoyme UB. Immunotherapy of gynaecological high-risk human papillomavirus infection with human leukocyte ultrafiltrate. Infect Dis Obstet Gynecol 2000;8(3-4):120-3.
136. Arany I, Rady P, Tyring SK, et al. Interferon treatment enhances the expression of under-phosphorylated (biologically active) retinoblastoma protein in human papilloma virus-infected cells through the inhibitory TGF beta 1/IFN beta cytokine pathway. Antiviral Res 1994;23:131.
137. Arany I, Tyring SK. Activation of local cell-mediated immunity in interferon-responsive patients with human papillomavirus-associated lesions. J Interferon Cytokine Res 1996;16:453.
138. Backe J, Roos T, Kaesemann H, et al. Local therapy and adjuvant interferon therapy in genital papilloma virus infections. Gynakol Geburtshilfliche Rundsch 1995;35:79.
139. Markowska J, Nowak M, Niecewicz R, et al. Results of topical treatment of HPV infection in the uterine cervix using interferon beta, 13-cis-retinoic acid and TFX. Eur J Gynaecol Oncol 1994;15:65.
140. El-Sherif AM, Seth R, Tighe PJ, et al. Quantitative analysis of IL-10 and IFN-gamma mRNA levels in normal cervix and human papillomavirus type 16 associated cervical precancer. J Pathol 2001;195:179-85.
141. Toma S, Ragni N, Raffo P, et al. Efficacy of the association of 13-cis-retinoic acid (13cRA) and alpha-interferon 2a (alpha-IFN 2a) in moderate-severe cervical intraepithelial neoplasia (CIN II-III): A pilot study. Anticancer Res 1996;16:931-6.
142. Gonzalez-Sanchez JL, Martinez-Chequer JC, Hernandez-Celaya ME, et al. Randomized placebo-controlled evaluation of intramuscular interferon beta treatment of recurrent human papillomavirus. Obstet Gynecol 2001;97:621-4.
143. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000;43:S6-11.
144. Hengge UR, Benninghoff B, Ruzicka T, et al. Topical immunomodulators-progress towards treating inflammation, infection, and cancer. Lancet Infect Dis 2001;1:189-98.
145. Arany I, Tyring SK, Stanley MA, et al. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res 1999;43:55-63.
146. Arrese J, Paquet P, Claessens N, et al. Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. J Cutan Pathol 2001;28:131-4.
147. Stem PL, Faulkner R, Veranes EC, et al. Best practice and research. Res Clin Obstet Gynaecol 2001;5:790
148. Chen DZ, Qi M, Aubom KJ, Carter TH. Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV16-transgenic preneoplastic cervical epithelium. J Nutr 2001;131:3294-302.
149. Bell MC, Crowley-Nowick P, Bradlow HL, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 2000;78:123-9.
150. Snoeck R, Andrei G, De Clercq E. Cidofovir in the treatment of HPV-associated lesions, Verh K Acad Geneeskd Belg 2001;63(2):93-120.
151. Snoeck R, Noel JC, Muller C, et al. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J Med Virol 2000;60(2):205-9.
152. Pahemik SA, Botzlar A, Hillemanns P, et al. Goetz AE pharmacokinetics and selectivity of aminolevulinic acid-induced porphyrin synthesis in patients with cervical intra-epithelial neoplasia. Int J Cancer 1998;78:310-4.
153. Hillemanns P, Korell M, Schmitt-Sody M, et al. Photodynamic therapy in women with cervical intraepithelial neoplasia using topically applied 5-aminolevulinic acid. Int J Cancer 1999;81:34-8.
154. Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M, et al. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res 2001;61:192-6.
155. Keefe KA, Chahine EB, DiSaia PJ, et al. Fluorescence detection of cervical intraepithelial neoplasia for photodynamic therapy with the topical agents 5-aminolevulinic acid and benzoporphyrin-derivative monoacid ring. Am J Obstet Gynecol 2001;184:1164-9.
156. Monk BJ, Brewer C, VanNostrand K, et al. Photodynamic therapy using topically applied dihematoporphyrin ether in the treatment of cervical intraepithelial neoplasia. Gynecol Oncol 1997;64:70-5.